Shire Regenerative Medicine, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2003-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://abh.com
Clinical Trials
7
Active:5
Completed:1
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Phase 3
Completed
- Conditions
- Venous Leg Ulcer
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Shire Regenerative Medicine, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT01891760
- Locations
- 🇺🇸
Carl T. Hayden VA Medical Center, Phoenix, Arizona, United States
🇺🇸Hope Research Institute, Phoenix, Arizona, United States
🇺🇸Dr. Jagpreet S. Mukker, Fresno, California, United States
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing
Phase 3
Terminated
- Conditions
- Epidermolysis Bullosa
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Shire Regenerative Medicine, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT01749306
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Lucile Packard Children's Hospital at Stanford University, Redwood City, California, United States
🇺🇸Rady Children's Hospital - San Diego/UCSD, Pediatric and Adolescent Dermatology, San Diego, California, United States
News
No news found